Pharma Focus Asia

Novartis's new strategic biomedical R&D center in Shanghai

  • Integrated Research & Development center, the first Novartis site of its kind in China
  • Primary focus on infectious causes of cancer endemic to China and Asia
  • Center will capitalize on talent in emerging life sciences cluster in Shanghai
  • Initial investment of USD 100 million to create Shanghai site - set to begin  operations in May 2007

Novartis announced plans to build an integrated biomedical Research & Development center in Shanghai's Zhangjiang Hi-Tech Park. The establishment of this site is a commitment by Novartis to conduct cutting-edge pharmaceutical research and development in China.

Research and development activities at the site will initially focus on addressing urgent medical needs in China and Asia, particularly infectious causes of cancer endemic to the region.

Expansion of global Novartis R&D network

The center will become the eighth site within Novartis Research and Development network. It will be staffed primarily by scientists recruited from Shanghai's emerging cluster of innovative academic, biotech and pharmaceuticals research institutions.

Scientists will initially work in a 5,000 square meter start-up facility that is expected to open in May 2007. Construction of a permanent 38,000 square meter facility for approximately 400 scientists will begin in July 2007. An investment of USD 100 million has been planned for the design and construction of the two facilities.

Focus on diseases prevalent in China

An initial area of research will be infectious causes of cancer. One disease is liver cancer caused by the hepatitis viruses. Some one-third of the 400 million people infected with the hepatitis B virus are in China, with experts estimating that the virus kills 300,000 people in mainland China each year.

The site will also include an integrated exploratory development center that will closely collaborate with basic research and local academic centers to further develop the concept of mechanism-based medicine and leverage emerging new technologies.

Specifications Table:

  • Company Name
  • Novartis
  • Location
  • Shanghai
  • Plant Type
  • Research center
  • Date of Start
  • 2007
  • Date of Completion
  • 2007
  • Estimated Investment
  • $100 Million
  • Key players
  •  
  • Sponsors/Partners
  • Novartis
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?